title: CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat.
abstract: OBJECTIVE
  Calcitonin gene-related peptide (CGRP) receptor antagonists effectively abort migraine headache and inhibit neurogenic vasodilatation in humans as well as rat models. Monoclonal antibodies typically have long half-lives, and we investigated whether or not function-blocking CGRP antibodies would inhibit neurogenic vasodilatation with a long duration of action and therefore be a possible approach to preventive therapy of migraine. During chronic treatment with anti-CGRP antibodies, we measured cardiovascular function, which might be a safety concern of CGRP inhibition.
  
  
  METHODS
  We used two rat blood flow models that measure electrically stimulated vasodilatation in the skin or in the middle meningeal artery (MMA). These vasomotor responses are largely dependent on the neurogenic release of CGRP from sensory afferents. To assess cardiovascular function during chronic systemic anti-CGRP antibody treatment, we measured heart rate and blood pressure in conscious rats.
  
  
  RESULTS
  Treatment with anti-CGRP antibodies inhibited skin vasodilatation or the increase in MMA diameter to a similar magnitude as treatment with CGRP receptor antagonists. Although CGRP antibody treatment had a slower onset of action than the CGRP receptor antagonists, the inhibition was still evident 1 week after dosing. Chronic treatment with anti-CGRP antibodies had no detectable effects on heart rate or blood pressure.
  
  
  CONCLUSIONS
  We showed for the first time that anti-CGRP antibodies exert a long lasting inhibition of neurogenic vasodilatation in two different rat models of arterial blood flow. We have provided strong preclinical evidence that anti-CGRP antibody may be a suitable drug candidate for the preventive treatment of migraine.
authors.affiliation: Rinat Laboratories, Biotherapeutics and Bioinnovation Center, Pfizer Inc., South San Francisco, CA 94080, USA.
authors.forename: J
authors.initials: J
authors.lastname: Zeller
authors.forename: K T
authors.initials: KT
authors.lastname: Poulsen
authors.forename: J E
authors.initials: JE
authors.lastname: Sutton
authors.forename: Y N
authors.initials: YN
authors.lastname: Abdiche
authors.forename: S
authors.initials: S
authors.lastname: Collier
authors.forename: R
authors.initials: R
authors.lastname: Chopra
authors.forename: C A
authors.initials: CA
authors.lastname: Garcia
authors.forename: J
authors.initials: J
authors.lastname: Pons
authors.forename: A
authors.initials: A
authors.lastname: Rosenthal
authors.forename: D L
authors.initials: DL
authors.lastname: Shelton
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000493:pharmacokinetics; D001794:Blood Pressure / Q000187:drug effects; D015740:Calcitonin Gene-Related Peptide / Q000037:antagonists & inhibitors* / Q000276:immunology; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D004195:Disease Models, Animal; D004558:Electric Stimulation; D006207:Half-Life; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D008576:Meningeal Arteries / Q000187:drug effects / Q000378:metabolism; D008881:Migraine Disorders / Q000503:physiopathology / Q000517:prevention & control; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D012867:Skin / Q000098:blood supply / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D015740:Calcitonin Gene-Related Peptide
references.citation: Nature. 1975 Aug 7;256(5517):495-7
references.pmid: 1172191
references.citation: Ann Neurol. 1987 May;21(5):431-7
references.pmid: 2438992
references.citation: Br J Pharmacol. 1999 Mar;126(6):1478-86
references.pmid: 10217543
references.citation: Cephalalgia. 1997 Jun;17(4):518-24
references.pmid: 9209773
references.citation: Nature. 1983 Jul 14-20;304(5922):129-35
references.pmid: 6346105
references.citation: Mol Interv. 2005 Oct;5(5):304-11
references.pmid: 16249526
references.citation: Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16702-7
references.pmid: 17923674
references.citation: N Engl J Med. 2004 Mar 11;350(11):1073-5
references.pmid: 15014178
references.citation: Clin Sci (Lond). 1995 Dec;89(6):565-73
references.pmid: 8549074
references.citation: Gastroenterology. 1993 May;104(5):1371-80
references.pmid: 8387040
references.citation: Hypertension. 2000 Jan;35(1 Pt 2):470-5
references.pmid: 10642343
references.citation: Gen Pharmacol. 1998 Jan;30(1):5-11
references.pmid: 9457475
references.citation: Ann Neurol. 1990 Aug;28(2):183-7
references.pmid: 1699472
references.citation: Peptides. 1993 Nov-Dec;14(6):1225-9
references.pmid: 7510881
references.citation: Br J Pharmacol. 2007 Mar;150(5):633-40
references.pmid: 17245362
references.citation: Physiol Rev. 2004 Jul;84(3):903-34
references.pmid: 15269340
references.citation: Am J Physiol. 1990 Feb;258(2 Pt 2):R425-9
references.pmid: 2309935
references.citation: Brain. 1994 Jun;117 ( Pt 3):427-34
references.pmid: 7518321
references.citation: Curr Opin Pharmacol. 2007 Dec;7(6):563-9
references.pmid: 18029228
references.citation: Nature. 1982 Jul 15;298(5871):240-4
references.pmid: 6283379
references.citation: N Engl J Med. 2004 Mar 11;350(11):1104-10
references.pmid: 15014183
references.citation: Br J Pharmacol. 2004 Aug;142(7):1171-81
references.pmid: 15237097
references.citation: Br J Pharmacol. 2001 Jul;133(6):807-14
references.pmid: 11454653
references.citation: Nucleic Acids Res. 2003 Nov 1;31(21):e130
references.pmid: 14576330
references.citation: Peptides. 1985;6 Suppl 3:265-71
references.pmid: 3008119
references.citation: Nat Biotechnol. 2005 Sep;23(9):1126-36
references.pmid: 16151406
references.citation: Hybridoma. 1993 Feb;12(1):93-106
references.pmid: 8095920
references.citation: Circ Res. 2001 Nov 23;89(11):983-90
references.pmid: 11717154
references.citation: Peptides. 1995;16(3):421-4
references.pmid: 7651894
references.citation: Clin Pharmacol Ther. 2005 Mar;77(3):202-13
references.pmid: 15735614
references.citation: Cephalalgia. 1997 Jun;17(4):525-31
references.pmid: 9209774
references.citation: Cephalalgia. 1994 Oct;14(5):320-7
references.pmid: 7828188
references.citation: Eur J Immunol. 1976 Jul;6(7):511-9
references.pmid: 825377
references.citation: Microsc Res Tech. 2001 May 1;53(3):167-78
references.pmid: 11301492
references.citation: Eur J Pharmacol. 2007 Jul 12;567(1-2):117-24
references.pmid: 17477918
references.citation: Cephalalgia. 2002 Feb;22(1):54-61
references.pmid: 11993614
references.citation: Br J Pharmacol. 2000 Feb;129(3):420-3
references.pmid: 10711339
references.citation: Regul Pept. 1986 Aug;15(1):1-23
references.pmid: 3532219
references.citation: Eur J Pharmacol. 1993 Nov 30;250(1):201-3
references.pmid: 8119320
references.citation: J Cereb Blood Flow Metab. 1987 Dec;7(6):720-8
references.pmid: 3500957
references.citation: Br J Pharmacol. 2006 Jun;148(4):536-43
references.pmid: 16633354
references.citation: Eur J Pharmacol. 2004 Oct 1;500(1-3):315-30
references.pmid: 15464043
references.citation: Br J Pharmacol. 1993 Oct;110(2):772-6
references.pmid: 8242250
references.citation: Eur J Pharmacol. 2007 May 7;562(1-2):103-10
references.pmid: 17349622
references.citation: J Pharmacol Exp Ther. 2001 Aug;298(2):551-8
references.pmid: 11454916
references.citation: Science. 1985 Sep 13;229(4718):1094-7
references.pmid: 2994212
references.citation: Br J Pharmacol. 2008 Mar;153 Suppl 2:S1-209
references.pmid: 18347570
references.citation: Br J Pharmacol. 2004 Nov;143(6):697-704
references.pmid: 15504760
references.citation: Neurology. 2008 Apr 15;70(16):1304-12
references.pmid: 17914062
references.citation: Pathol Biol (Paris). 1992 Apr;40(4):313-7
references.pmid: 1379707
references.citation: Eur J Pharmacol. 2003 Aug 15;475(1-3):69-77
references.pmid: 12954361
references.citation: J Auton Nerv Syst. 1989 Feb;26(1):69-75
references.pmid: 2785130
references.citation: Mol Cell Neurosci. 1999 Aug;14(2):99-120
references.pmid: 10532808
references.citation: Br J Pharmacol. 2005 Sep;146(1):7-14
references.pmid: 15980877